Complement factors and their receptors. Immunopharmacology ; 38 :3— Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res ; 37 — Wetsel RA. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol ; 7 — Cloning and functional characterization of the mouse C3a anaphylatoxin receptor gene.
Immunogenetics ; 47 — Cloning, expression, sequence determination, and chromosome localization of the mouse complement C3a anaphylatoxin receptor gene. Mol Immunol ; 35 — Article Google Scholar. Genomics ; 13 — Cellular expression of the C5a anaphylatoxin receptor C5aR : demonstration of C5aR on nonmyeloid cells of the liver and lung. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol ; — The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview.
Biochimie ; 89 — Eur J Biochem ; — Eur J Immunol ; 27 — Mol Pharmacol ; 46 — Specific interactions of chemoattractant factor receptors with G-proteins. Mapping of the C5a receptor signal transduction network in human neutrophils. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. Expression of a functional anaphylatoxin C3a receptor by astrocytes.
J Neurochem ; 71 — Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis ; — High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am J Kidney Dis ; 49 — Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol ; 86 — Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.
J Invest Dermatol ; — Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol Lett ; 88 — Expression of the anaphylatoxin C5a receptor in non-myeloid cells.
Mol Immunol ; 36 — Membrane complement receptors specific for bound fragments of C3. Adv Immunol ; 37 — Macrophage complement receptors and pathogen clearance. Cell Microbiol ; 9 — Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med ; — Immunity ; 7 — Structure-function relationships of complement receptor type 1.
Immunol Rev ; — Ross GD. Crit Rev Immunol ; 20 — CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Progress in Immunology. New York: Academic, Pepys MB. Role of complement in induction of the allergic response. Nat New Biol ; — Complement, membrane glycoproteins, and complement receptors: their role in regulation of the immune response.
Clin Immunol Immunopathol ; 40 — Role of C3 in humoral immunity. Defective antibody production in C3-deficient dogs. Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol ; 4 — Carroll MC. The complement system in B cell regulation. Complement and humoral immunity.
Vaccine ; 26 Suppl 8 :I28— Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor.
Int Immunol ; 2 — Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. CD lowering the threshold for antigen receptor stimulation of B lymphocytes. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.
Transitional B cells are the target of negative selection in the B cell compartment. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. Functional activity of natural antibody is altered in Cr2-deficient mice. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.
Immunity ; 4 — Follicular stromal cells and lymphocyte homing to follicles. Fischer W, Hugli T. Anaphylatoxin-mediated regulation of the immune response. C3a-mediated suppression of human and murine humoral immune responses. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. Chemotaxis of germinal center B cells in response to C5a. Eur J Immunol ; 21 — Annu Rev Immunol ; 18 — Absence of marginal zone B cells in Pykdeficient mice defines their role in the humoral response.
Nat Immunol ; 1 — Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice.
Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Humoral response to herpes simplex virus is complement-dependent.
Mehlhop E, Diamond MS. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. Immunity ; 17 — Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.
Nat Med ; 8 — Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Decay-accelerating factor modulates induction of T cell immunity. Immunity ; 28 — Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. Activated human T lymphocytes express a functional C3a receptor. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.
Immunology ; 97 — Human T cells express the C5a receptor and are chemoattracted to C5a. The C5a chemoattractant receptor mediates mucosal defence to infection. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Hawlisch H, Kohl J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol Immunol ; 43 — Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol ; 5 — Cattaneo R.
Four viruses, two bacteria, and one receptor: membrane cofactor protein CD46 as pathogens' magnet. J Virol ; 78 — Mechanism of suppression of cell-mediated immunity by measles virus.
Mold C. Role of complement in host defense against bacterial infection. Microbes Infect ; 1 — Ross SC, Densen P.
It is well known that both IgG and IgM can activate complement via the classical pathway by binding of C1q to the Fc regions of these immunoglobulins. Recent advances have shown that also IgA is capable of activating the complement system. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.
J Clin Invest. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of cases. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. Glomerular C3d as a novel prognostic marker for renal vasculitis. Hum Pathol. Clin J Am Soc Neph. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.
Antiphospholipid syndrome. Nat Rev Dis Prim. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor.
Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.
Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.
Arthritis Rheum. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy.
Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.
A new role for complement in experimental membranous nephropathy in rats. Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Koneczny I. A new classification system for IgG4 autoantibodies. Membranous nephropathy: from models to man.
Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency. Meta-analysis of molecular response of kidney to ischemia reperfusion injury for the identification of new candidate genes. Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies.
Am J Kidney Dis. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. Contrasting roles of complement activation and its regulation in membranous nephropathy. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.
Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. Gilhus NE. Myasthenia gravis. Immune complexes IgG and C3 at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.
Mayo Clin Proc. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Christadoss P. C5 gene influences the development of murine myasthenia gravis. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol. Soluble complement receptor 1 sCR1 protects against experimental autoimmune myasthenia gravis. J Neuroimmunol. Biesecker G, Gomez CM. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis REGAIN : a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Lancet Neurol. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Evidence for classic complement activity in neuromyelitis optica. Clin Neuropathol. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
Asavapanumas N, Verkman AS. Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta Neuropathol Commun. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms. Immunol Res ; — Miletic, V. D, Hester, C. G, Frank, M. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Neuroimmunol ; — Kissel, J. T, Mendell, J. N Engl J Med ; — Petz, L. D, Catlett, J.
J Clin Invest ; — Lutz, HU, Stammler, P. Lutz, H. Basta, M et al.
0コメント